BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Kendall Jenner addresses long-standing rumor about her sexuality- Ryan Gosling responds to Deidre Hall's invitation to visit the 'Days of Our Lives' set: 'This is a very enthusiastic yes'
- Instructions to Floss Appropriately and Forestall Gum Sickness
- Dad issues urgent plea to find stem cell donor for his son
- 7 Odd Apparatuses to Make Your Party Stick Out!
- Hundreds of kilos of protected plant seized by Israel Nature and Parks Authority in Golan
- 'Pluribus' release date: Everything you need to know about the new series from 'Better Call Saul's' co-creator
- Artemis 2 moon rocket gets 'America 250' paint job | Space photo of the day for Dec. 23, 2025
- Dominating the Mastercard Endorsement Cycle: Six Fundamental Stages
